Profiling prostate cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 52, 2011, Pages 20861-20862

  Nelson, William G ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARVCF PROTEIN; CRYPTOCHROME 1; INTERLEUKIN 4; LEPR PROTEIN; MESSENGER RNA; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN; PROTEIN P53; RNASEL PROTEIN; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; CANCER RADIOTHERAPY; CANCER SURGERY; EMBRYONIC STEM CELL; GENE EXPRESSION PROFILING; GLEASON SCORE; HUMAN; NOTE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN EXPRESSION;

HUMANS; MALE; NEOPLASM GRADING; PROSTATIC NEOPLASMS; RNA, MESSENGER;

EID: 84855494642     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1118444109     Document Type: Note

References (15)

1. Jemal A, et al. (2011) Global cancer statistics. CA Cancer J Clin 61:69-90.
2. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212-236.
3. Schröder FH, et al.; ERSPC Investigators (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-1328.
4. Schröder FH (2011) Stratifying risk - the U.S. Preventive Services Task Force and prostate-cancer screening. N Engl J Med 365:1953-1955.
5. Tosoian JJ, et al. (2011) Active surveillance program for prostate cancer: An update of the Johns Hopkins experience. J Clin Oncol 29:2185-2190.
6. Markert EK, Mizuno H, Vazquez A, Levine AJ (2011) Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci USA 108:21276-21281.
7. Hernandez DJ, et al. (2008) Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy. Urology 72:172-176.
8. Morris DS, et al. (2007) Integrating biomedical knowledge to model pathways of prostate cancer progression. Cell Cycle 6:1177-1187. (Pubitemid 47333814)
9. Nelson WG, De Marzo AM, Yegnasubramanian S (2009) Epigenetic alterations in human prostate cancers. Endocrinology 150:3991-4002.
10. Mizuno H, Spike BT, Wahl GM, Levine AJ (2010) Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures. Proc Natl Acad Sci USA 107:22745-22750.
11. Sboner A, et al. (2010) Molecular sampling of prostate cancer: A dilemma for predicting disease progression. BMC Med Genomics 3:8.
12. Taylor BS, et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18:11-22.
13. Kim J, et al. (2011) A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53. Oncogene, 10.1038/onc.2011.236.
14. Lin DW, et al. (2011) Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev 20:1928-1936.
15. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI (2003) Pathological and molecular aspects of prostate cancer. Lancet 361:955-964. (Pubitemid 36332115)